帕博利珠单抗是一种人源化的抗PD-1单克隆抗体,能够增强抗肿瘤免疫活性。近日,一篇发表在国际杂志Nature Medicine上,标题为《Oncolytic adenoviral therapy plus Pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the ph...
参考资料：1.https://www.businesswire.com/news/home/20211113005249/en/CG-Oncology-Presents-Preliminary-Phase-2-Data-with-CG0070-in-Combination-with-KEYTRUDA%C2%AE-pembrolizumab-in-Non-Muscle-Invasive-Bladder-Cancer-Unresponsive-to-Bacillus-Calmette-Guerin 2.乐普生物招股书 3.开心生活团队依据公开信息整...
参考出处 1.https://www.businesswire.com/news/home/20211113005249/en/CG-Oncology-Presents-Preliminary-Phase-2-Data-with-CG0070-in-Combination-with-KEYTRUDA%C2%AE-pembrolizumab-in-Non-Muscle-Invasive-Bladder-Cancer-Unresponsive-to-Bacillus-Calmette-Guerin 2.乐普生物招股书 3.开心生活团队依据公开信息整...
The safety and efficacy of the combination of the oncolytic immunotherapy CG0070 and nivolumab (Opdivo) is under exploration as a potential therapeutic option in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy, as part of the phase ...
The combination of CG0070 and pembrolizumab was well tolerated and demonstrated early signals of activity in patients with Bacille Calmette-Guérin-unresponsive non–muscle invasive bladder cancer.
CG0070 has previously demonstrated safety and efficacy against BCG-exposed high risk non-muscle invasive bladder cancer through tumor lysis and anti-tumor immune activation. We tested the safety and efficacy of CG0070 in combination with N as neoadjuvant therapy for MIBC in C-ineligible patients in...
In an interview with Targeted Oncology, Roger Li, MD, discussed the use of the CG0070 in combination with pembrolizumab and nivolumab for patients with non-muscle invasive bladder cancer who are unresponsive to Bacillus Calmette-Guerin.
药物描述 CG0070 is investigated in clinical trials for treating bladder cancer. CG0070 is a solid. CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF. CG0070, an oncolytic virus therapy ...
1.https://www.businesswire.com/news/home/20211113005249/en/CG-Oncology-Presents-Preliminary-Phase-2-Data-with-CG0070-in-Combination-with-KEYTRUDA%C2%AE-pembrolizumab-in-Non-Muscle-Invasive-Bladder-Cancer-Unresponsive-to-Bacillus-Calmette-Guerin ...
Participation in global Phase III clinical trial for CG0070, a drug for bladder cancerwww....